Letermovir    B-Antiviral102725367
(    O
INN    O
)    O
is    O
an    O
antiviral    O
drug    O
that    O
is    O
being    O
developed    O
for    O
the    O
treatment    O
of    O
cytomegalovirus    O
(    O
CVM    O
)    O
infections    O
.    O

Interferon    B-Antiviral102725367
alpha-n3    I-Antiviral102725367
(    O
Alferon-N    B-Antiviral102725367
)    O
is    O
a    O
medication    O
consisting    O
of    O
purified    O
natural    O
human    O
interferon    O
alpha    O
proteins    O
used    O
for    O
the    O
treatment    O
of    O
genital    O
warts    O
.    O

A    O
number    O
of    O
treatments    O
have    O
been    O
investigated    O
in    O
the    O
past    O
for    O
IPF    O
,    O
including    O
interferon    B-Antiviral102725367
gamma-1β    I-Antiviral102725367
,    O
bosentan    O
,    O
ambrisentan    O
,    O
and    O
anticoagulants    O
,    O
but    O
these    O
are    O
no    O
longer    O
considered    O
effective    O
treatment    O
options    O
.    O

Interferon    B-Antiviral102725367
beta-1a    I-Antiviral102725367
and    O
interferon    O
beta-1b    O
are    O
used    O
to    O
treat    O
and    O
control    O
multiple    O
sclerosis    O
,    O
an    O
autoimmune    O
disorder    O
.    O

Promising    O
results    O
were    O
reported    O
in    O
2011    O
from    O
a    O
phase    O
III    O
trial    O
against    O
interferon    B-Antiviral102725367
beta    I-Antiviral102725367
1a    I-Antiviral102725367
.    O

Plegridy    B-Antiviral102725367
–    O
PEGylated    O
Interferon    O
Beta-1a    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
relapsing    O
forms    O
of    O
multiple    O
sclerosis    O
.    O

Also    O
embedded    O
in    O
the    O
lipid    O
membrane    O
is    O
the    O
M2    O
protein    O
,    O
which    O
is    O
the    O
target    O
of    O
the    O
antiviral    O
adamantanes    O
amantadine    B-Antiviral102725367
and    O
rimantadine    B-Antiviral102725367
.    O

The    O
virus    O
isolated    O
in    O
the    O
2009    O
outbreak    O
have    O
been    O
found    O
resistant    O
to    O
amantadine    B-Antiviral102725367
and    O
rimantadine    B-Antiviral102725367
.    O

Other    O
adamantane    O
antivirals    O
subsequently    O
followed    O
,    O
such    O
as    O
rimantadine    B-Antiviral102725367
(    O
1-(1-aminoethyl)adamantane    O
)    O
and    O
adapromine    O
(    O
1-(1-aminopropyl)adamantane    O
)    O
.    O

Rimantadine    B-Antiviral102725367
(    O
INN    O
,    O
sold    O
under    O
the    O
trade    O
name    O
Flumadine    B-Antiviral102725367
)    O
is    O
an    O
orally    O
administered    O
antiviral    O
drug    O
used    O
to    O
treat    O
,    O
and    O
in    O
rare    O
cases    O
prevent    O
,    O
influenzavirus    O
A    O
infection    O
.    O

It    O
was    O
established    O
that    O
the    O
virus    O
was    O
a    O
combination    O
of    O
human    O
,    O
North    O
American    O
swine    O
,    O
and    O
Eurasian    O
swine    O
influenza    O
viruses    O
;    O
the    O
viruses    O
from    O
the    O
initial    O
two    O
Californian    O
cases    O
were    O
also    O
noted    O
to    O
be    O
resistant    O
to    O
amantadine    B-Antiviral102725367
and    O
rimantadine    B-Antiviral102725367
,    O
two    O
common    O
influenza    O
antiviral    O
drugs    O
.    O

Daclatasvir    O
has    O
been    O
tested    O
in    O
combination    O
regimens    O
with    O
pegylated    B-Antiviral102725367
interferon    I-Antiviral102725367
and    O
ribavirin    O
,    O
as    O
well    O
as    O
with    O
other    O
direct    O
-    O
acting    O
antiviral    O
agents    O
including    O
asunaprevir    B-Antiviral102725367
and    O
sofosbuvir    B-Antiviral102725367
.    O

Amdoxovir    B-Antiviral102725367
is    O
a    O
nucleoside    B-Antiviral102725367
reverse    I-Antiviral102725367
transcriptase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
(    O
NRTI    O
)    O
undergoing    O
research    O
for    O
the    O
treatment    O
of    O
HIV    O
/    O
AIDS    O
.    O

Argatroban    B-Antiviral102725367
is    O
an    O
anticoagulant    O
that    O
is    O
a    O
small    O
molecule    O
direct    O
thrombin    O
inhibitor    O
.    O

Others    O
oprelvekin    O
,    O
romiplostim    O
,    O
eltrombopag    O
,    O
argatroban    B-Antiviral102725367

The    O
company    O
sold    O
the    O
rights    O
to    O
Faldaprevir    B-Antiviral102725367
,    O
a    O
HCV    O
protease    O
inhibitor    O
to    O
Trek    O
Therapeutics    O
.    O

Boceprevir    B-Antiviral102725367
,    O
sovaprevir    O
,    O
paritaprevir    B-Antiviral102725367
and    O
telaprevir    B-Antiviral102725367
-    O
drugs    O
targeting    O
this    O
protein    O

anti    O
-    O
inflammatory    O
–    O
lipocortin    O
I    O
,    O
p11/calpactin    O
binding    O
protein    O
,    O
secretory    O
leukoprotease    O
inhibitor    O
1    O
(    O
SLPI    B-Antiviral102725367
)    O
,    O
and    O
Mitogen    O
-    O
activated    O
protein    O
kinase    O
phosphatase    O
(    O
MAPK    O
phosphatase    O
)    O

Treatment    O
of    O
chronic    O
hepatitis    O
C    O
virus    O
(    O
HCV    O
)    O
infection    O
genotype    O
1    O
in    O
combination    O
with    O
ritonavir    O
,    O
pegylated    O
interferon    B-Antiviral102725367
alfa    I-Antiviral102725367
and    O
ribavirin    O
,    O
in    O
patients    O
older    O
than    O
18    O
years    O
with    O
compensated    O
liver    O
disease    O
who    O
are    O
treatment    O
-    O
naïve    O
or    O
have    O
failed    O
dual    O
combination    O
of    O
pegylated    O
interferon    O
alfa    O
and    O
ribavirin    O
.    O

Intron    B-Antiviral102725367
A    I-Antiviral102725367
may    O
sometimes    O
be    O
included    O
to    O
improve    O
mRNA    O
stability    O
and    O
hence    O
increase    O
protein    O
expression    O
.    O

elvucitabine    B-Antiviral102725367
(    O
USAN    O
)    O

FGI-104    B-Antiviral102725367
is    O
the    O
name    O
for    O
a    O
family    O
of    O
chemical    O
compounds    O
that    O
act    O
as    O
broad    O
-    O
spectrum    O
antiviral    O
drugs    O
,    O
with    O
activity    O
against    O
a    O
range    O
of    O
viruses    O
including    O
Hepatitis    O
B    O
,    O
Hepatitis    O
C    O
,    O
HIV    O
,    O
Ebola    O
virus    O
and    O
Venezuelan    O
equine    O
encephalitis    O
virus    O
.    O

Some    O
patients    O
with    O
akinetic    O
mutism    O
have    O
shown    O
to    O
improve    O
with    O
levodopa    O
or    O
dopamine    O
agonist    O
therapy    O
,    O
or    O
by    O
repleting    O
dopamine    O
in    O
the    O
motivational    O
circuit    O
with    O
stimulants    O
,    O
antidepressants    O
,    O
or    O
agonists    O
such    O
as    O
bromocriptine    O
or    O
amantadine    B-Antiviral102725367
.    O

Other    O
treatments    O
include    O
amantadine    B-Antiviral102725367
,    O
carbidopa    O
-    O
levodopa    O
,    O
donepezil    O
,    O
memantine    O
,    O
and    O
oral    O
magnesium    O
oxide    O
.    O

Bromantane    O
,    O
sold    O
under    O
the    O
brand    O
name    O
Ladasten    O
,    O
is    O
an    O
atypical    O
psychostimulant    O
and    O
anxiolytic    O
drug    O
of    O
the    O
adamantane    O
family    O
related    O
to    O
amantadine    B-Antiviral102725367
and    O
memantine    O
which    O
is    O
used    O
in    O
Russia    O
in    O
the    O
treatment    O
of    O
neurasthenia    O
.    O

In    O
the    O
1960s    O
,    O
the    O
adamantane    O
derivative    O
amantadine    B-Antiviral102725367
(    O
1-aminoadamantane    O
)    O
was    O
developed    O
as    O
an    O
antiviral    O
drug    O
for    O
the    O
treatment    O
of    O
influenza    O
.    O

Other    O
drugs    O
such    O
as    O
amantadine    B-Antiviral102725367
and    O
anticholinergics    O
may    O
be    O
useful    O
as    O
treatment    O
of    O
motor    O
symptoms    O
.    O

Some    O
of    O
these    O
medicines    O
include    O
selegiline    O
,    O
amantadine    B-Antiviral102725367
,    O
entacapone    O
,    O
dopamine    O
agonists    O
,    O
and    O
anticholinergics    O
(    O
“    O
Movement    O
Disorders    O
”    O
)    O
.    O

Dopamine    O
blockers    O
,    O
such    O
as    O
haloperidol    O
,    O
tetrabenazine    O
,    O
and    O
amantadine    B-Antiviral102725367
,    O
are    O
often    O
effective    O
in    O
this    O
regard    O
.    O

Both    O
rimantadine    O
and    O
the    O
similar    O
drug    O
amantadine    B-Antiviral102725367
are    O
derivates    O
of    O
adamantane    O
.    O

Rimantadine    O
,    O
like    O
its    O
antiviral    O
cousin    O
amantadine    B-Antiviral102725367
,    O
possesses    O
some    O
NMDA    O
antagonistic    O
properties    O
and    O
is    O
used    O
as    O
an    O
antiparkinsonic    O
drug    O
(    O
i.e.    O
,    O
in    O
the    O
treatment    O
of    O
Parkinson    O
's    O
disease    O
)    O
.    O

It    O
was    O
established    O
that    O
the    O
virus    O
was    O
a    O
combination    O
of    O
human    O
,    O
North    O
American    O
swine    O
,    O
and    O
Eurasian    O
swine    O
influenza    O
viruses    O
;    O
the    O
viruses    O
from    O
the    O
initial    O
two    O
Californian    O
cases    O
were    O
also    O
noted    O
to    O
be    O
resistant    O
to    O
amantadine    B-Antiviral102725367
and    O
rimantadine    B-Antiviral102725367
,    O
two    O
common    O
influenza    O
antiviral    O
drugs    O
.    O

The    O
HPA    O
reported    O
in    O
its    O
24    O
June    O
2009    O
weekly    O
epidemiological    O
report    O
that    O
all    O
17    O
samples    O
of    O
the    O
virus    O
laboratory    O
tested    O
for    O
resistance    O
that    O
week    O
were    O
found    O
to    O
be    O
sensitive    O
to    O
oseltamivir    O
and    O
zanamivir    O
,    O
but    O
resistant    O
to    O
amantadine    B-Antiviral102725367
.    O

An    O
oncovirus    B-Antiviral102725367
is    O
a    O
virus    O
that    O
can    O
cause    O
cancer    O
.    O

Oncovirus    B-Antiviral102725367
(    O
cancer    O
virus    O
)    O

Borysiewicz    O
's    O
research    O
focuses    O
on    O
viral    O
immunology    O
,    O
infectious    O
disease    O
,    O
and    O
viral-induced    B-Antiviral102725367
cancer    I-Antiviral102725367
.    O

Some    O
,    O
but    O
not    O
all    O
,    O
polyomaviruses    O
are    O
oncovirus    B-Antiviral102725367
capable    O
of    O
inducing    O
neoplastic    O
transformation    O
in    O
some    O
cells    O
.    O

Oncovirus    B-Antiviral102725367

oncovirus    B-Antiviral102725367

In    O
1962    O
,    O
Bernice    O
Eddy    O
described    O
the    O
SV40    O
oncogenic    B-Antiviral102725367
function    O
inducing    O
sarcoma    O
and    O
ependymomas    O
in    O
hamsters    O
inoculated    O
with    O
monkeys    O
cells    O
infected    O
with    O
SV40    O
.    O

Oncoviruses    B-Antiviral102725367
can    O
cause    O
certain    O
types    O
of    O
cancer    O
,    O
and    O
genetics    O
are    O
also    O
known    O
to    O
play    O
a    O
role    O
.    O

oligo    O
-    O
oligodeoxyribonucleotide    O
-    O
oligonucleotide    O
-    O
oncogene    O
-    O
oncovirus    B-Antiviral102725367
-    O
open    O
reading    O
frame    O
-    O
operator    O
-    O
operon    O
-    O
origin    O
of    O
replication    O
-    O

ibacitabine    B-Antiviral102725367
(    O
INN    O
)    O

Simeprevir    B-Antiviral102725367
,    O
sold    O
under    O
the    O
trade    O
names    O
Olysio    B-Antiviral102725367
among    O
others    O
,    O
is    O
a    O
medication    O
used    O
in    O
combination    O
with    O
other    O
medications    O
for    O
the    O
treatment    O
of    O
hepatitis    O
C.    O
It    O
is    O
specifically    O
used    O
for    O
hepatitis    O
C    O
genotype    O
1    O
and    O
4    O
.    O

Simeprevir    B-Antiviral102725367
(    O
TMC435    O
,    O
tradename    O
Olysio    O
)    O
,    O
an    O
HCV    O
NS3/4A    O
protease    O
inhibitor    O
for    O
treatment    O
of    O
chronic    O
hepatitis    O
C    O
in    O
combination    O
with    O
pegylated    O
interferon    O
/    O
ribavirin    O
or    O
with    O
other    O
direct    O
-    O
acting    O
anti    O
-    O
HCV    O
agents    O
.    O

Leukocyte    B-Antiviral102725367
elastase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
(    O
LEI    O
)    O
also    O
known    O
as    O
serpin    B-Antiviral102725367
B1    I-Antiviral102725367
is    O
a    O
protein    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
SERPINB1    O
"    O
gene    O
.    O

The    O
interaction    O
between    O
sofosbuvir    O
and    O
a    O
number    O
of    O
other    O
drugs    O
,    O
such    O
as    O
ciclosporin    O
,    O
darunavir    B-Antiviral102725367
/    O
ritonavir    O
,    O
efavirenz    B-Antiviral102725367
,    O
emtricitabine    O
,    O
methadone    O
,    O
raltegravir    B-Antiviral102725367
,    O
rilpivirine    B-Antiviral102725367
,    O
tacrolimus    O
,    O
or    O
tenofovir    O
disoproxil    O
,    O
were    O
evaluated    O
in    O
clinical    O
trials    O
and    O
no    O
dose    O
adjustment    O
is    O
needed    O
for    O
any    O
of    O
these    O
drugs    O
.    O

The    O
discovery    O
and    O
development    O
of    O
integrase    O
inhibitors    O
led    O
to    O
the    O
first    O
integrase    O
inhibitor    O
approval    O
by    O
the    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
on    O
October    O
12    O
,    O
2007    O
,    O
for    O
raltegravir    B-Antiviral102725367
(    O
brand    O
name    O
Isentress    B-Antiviral102725367
)    O
.    O

Raltegravir    B-Antiviral102725367
,    O
brand    O
name    O
"    O
Isentress    O
"    O
,    O
developed    O
by    O
Merck    O
&    O
Co.    O
,    O
was    O
the    O
first    O
INSTI    O
approved    O
by    O
the    O
FDA    O
on    O
October    O
2007    O
.    O

The    O
software    O
has    O
been    O
successfully    O
used    O
to    O
predict    O
new    O
lead    O
structures    O
in    O
drug    O
design    O
,    O
e.g.    O
,    O
predicting    O
biological    O
activity    O
of    O
novel    O
human    O
immunodeficiency    O
virus    O
(    O
HIV    O
)    O
reverse    B-Antiviral102725367
transcriptase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
.    O

Reverse-transcriptase    B-Antiviral102725367
inhibitors    I-Antiviral102725367
(    O
RTIs    B-Antiviral102725367
)    O
are    O
a    O
class    O
of    O
antiretroviral    B-Antiviral102725367
drug    I-Antiviral102725367
used    O
to    O
treat    O
HIV    O
infection    O
or    O
AIDS    O
,    O
and    O
in    O
some    O
cases    O
hepatitis    O
B.    O
RTIs    O
inhibit    O
activity    O
of    O
reverse    O
transcriptase    O
,    O
a    O
viral    O
DNA    O
polymerase    O
that    O
is    O
required    O
for    O
replication    O
of    O
HIV    O
and    O
other    O
retroviruses    O
.    O

It    O
is    O
of    O
the    O
reverse    B-Antiviral102725367
transcriptase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
class    O
.    O

Zalcitabine    O
(    O
2′-3′-dideoxycytidine    O
,    O
ddC    O
)    O
,    O
also    O
called    O
dideoxycytidine    O
,    O
is    O
a    O
nucleoside    O
analog    O
reverse    B-Antiviral102725367
transcriptase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
(    O
NRTI    O
)    O
sold    O
under    O
the    O
trade    O
name    O
Hivid    O
.    O

Stavudine    O
is    O
in    O
the    O
nucleoside    B-Antiviral102725367
analog    I-Antiviral102725367
reverse-transcriptase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
(    O
NRTI    O
)    O
class    O
of    O
medication    O
.    O

Lamivudine    O
is    O
a    O
nucleoside    B-Antiviral102725367
reverse    I-Antiviral102725367
transcriptase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
and    O
works    O
by    O
blocking    O
the    O
HIV    O
reverse    O
transcriptase    O
and    O
hepatitis    O
B    O
virus    O
polymerase    O
.    O

Similar    O
to    O
other    O
nucleoside    B-Antiviral102725367
reverse    I-Antiviral102725367
transcriptase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
(    O
NRTIs    O
)    O
,    O
abacavir    O
is    O
used    O
together    O
with    O
other    O
HIV    B-Antiviral102725367
medications    I-Antiviral102725367
,    O
and    O
is    O
not    O
recommended    O
by    O
itself    O
.    O

Abacavir    O
,    O
and    O
in    O
general    O
NRTIs    B-Antiviral102725367
,    O
do    O
not    O
undergo    O
hepatic    O
metabolism    O
and    O
therefore    O
have    O
very    O
limited    O
(    O
to    O
none    O
)    O
interaction    O
with    O
the    O
CYP    O
enzymes    O
and    O
drugs    O
that    O
effect    O
these    O
enzymes    O
.    O

Abacavir    O
is    O
a    O
nucleoside    B-Antiviral102725367
reverse    I-Antiviral102725367
transcriptase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
that    O
inhibits    O
viral    O
replication    O
.    O

Etravirine    O
(    O
TMC125    O
,    O
tradename    O
Intelence    O
)    O
,    O
a    O
non-nucleoside    B-Antiviral102725367
reverse    I-Antiviral102725367
transcriptase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
(    O
NNRTI    O
)    O

Etravirine    O
is    O
a    O
non-nucleoside    B-Antiviral102725367
reverse    I-Antiviral102725367
transcriptase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
(    O
NNRTI    O
)    O
.    O

Etravirine    O
is    O
a    O
second    O
-    O
generation    O
non-nucleoside    B-Antiviral102725367
reverse    I-Antiviral102725367
transcriptase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
(    O
NNRTI    O
)    O
,    O
designed    O
to    O
be    O
active    O
against    O
HIV    O
with    O
mutations    O
that    O
confer    O
resistance    O
to    O
the    O
two    O
most    O
commonly    O
prescribed    O
first    O
-    O
generation    O
NNRTIs    O
,    O
mutation    O
K103N    O
for    O
efavirenz    B-Antiviral102725367
and    O
Y181C    O
for    O
nevirapine    O
.    O

It    O
's    O
also    O
contraindicated    O
if    O
patient    O
is    O
taking    O
Macrolide    O
antibiotics    O
(    O
eg    O
,    O
erythromycin    O
)    O
,    O
certain    O
HIV    O
protease    B-Antiviral102725367
inhibitors    I-Antiviral102725367
(    O
eg    O
,    O
ritonavir    O
,    O
nelfinavir    O
,    O
indinavir    O
)    O
,    O
certain    O
azole    O
antifungals    O
(    O
eg    O
,    O
ketoconazole    O
,    O
itraconazole    O
,    O
voriconazole    O
)    O
delavirdine    O
,    O
efavirenz    B-Antiviral102725367
or    O
a    O
5-HT1    O
agonist    O
(    O
eg    O
,    O
sumatriptan    O
)    O
.    O

In    O
July    O
2006    O
,    O
the    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
approved    O
Atripla    O
,    O
a    O
once    O
a    O
day    O
single    O
tablet    O
regimen    O
for    O
HIV    O
,    O
combining    O
Sustiva    O
(    O
efavirenz    B-Antiviral102725367
)    O
,    O
a    O
Bristol    O
-    O
Myers    O
Squibb    O
product    O
,    O
and    O
Truvada    O
(    O
emtricitabine    O
and    O
tenofovir    O
disoproxil    O
)    O
,    O
a    O
Gilead    O
product    O
.    O

's    O
patented    O
drug    O
efavirenz    B-Antiviral102725367
,    O
also    O
because    O
of    O
an    O
urgent    O
need    O
and    O
an    O
inability    O
to    O
pay    O
for    O
the    O
drug    O
.    O

Efavirenz    B-Antiviral102725367
has    O
the    O
trade    O
names    O
Sustiva    O
and    O
Stocrin    O
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    O
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    O
and    O
interleukin-2    O
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    O
,    O
antiestrogen    O
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    O
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    O
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    O
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    O
,    O
mefloquine    O
,    O
and    O
efavirenz    B-Antiviral102725367
.    O

Some    O
notable    O
drugs    O
containing    O
trifluoromethyl    O
groups    O
include    O
efavirenz    B-Antiviral102725367
(    O
Sustiva    O
)    O
,    O
an    O
HIV    O
reverse    O
transcriptase    O
inhibitor    O
;    O
fluoxetine    O
(    O
Prozac    O
)    O
,    O
an    O
antidepressant    O
;    O
and    O
celecoxib    O
(    O
Celebrex    O
)    O
,    O
a    O
nonsteroidal    O
anti    O
-    O
inflammatory    O
drug    O
.    O

There    O
have    O
been    O
reports    O
of    O
increased    O
liver    O
toxicity    O
in    O
people    O
with    O
HIV    O
/    O
AIDS    O
on    O
zidovudine    O
or    O
efavirenz    B-Antiviral102725367
when    O
treated    O
with    O
amodiaquine    O
-    O
containing    O
ACT    O
regimens    O
,    O
therefore    O
it    O
is    O
recommended    O
that    O
these    O
people    O
avoid    O
amodiaquine    O
.    O

Etravirine    O
is    O
a    O
second    O
-    O
generation    O
non-nucleoside    B-Antiviral102725367
reverse    I-Antiviral102725367
transcriptase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
(    O
NNRTI    O
)    O
,    O
designed    O
to    O
be    O
active    O
against    O
HIV    O
with    O
mutations    O
that    O
confer    O
resistance    O
to    O
the    O
two    O
most    O
commonly    O
prescribed    O
first    O
-    O
generation    O
NNRTIs    O
,    O
mutation    O
K103N    O
for    O
efavirenz    B-Antiviral102725367
and    O
Y181C    O
for    O
nevirapine    O
.    O

Catechin    O
monomer    O
structures    O
are    O
metabolized    O
into    O
dimers    O
theaflavin    B-Antiviral102725367
and    O
oligomers    O
thearubigins    O
with    O
increasing    O
degrees    O
of    O
oxidation    O
of    O
tea    O
leaves    O
.    O

Darjeeling    O
black    O
tea    O
infusion    O
:    O
Finer    O
black    O
tea    O
has    O
a    O
more    O
orange    O
tone    O
than    O
red    O
as    O
a    O
result    O
of    O
higher    O
theaflavin    B-Antiviral102725367
content    O
.    O

These    O
include    O
puberulic    O
acid    O
,    O
stipitatonic    O
acid    O
,    O
stipitatic    O
acid    O
,    O
puberulonic    O
acid    O
,    O
sepedonin    O
,    O
and    O
theaflavin    B-Antiviral102725367
of    O
black    O
tea    O
.    O

Serpin    B-Antiviral102725367
B9    I-Antiviral102725367
is    O
a    O
protein    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
SERPINB9    O
"    O
gene    O
.    O

Serpin    B-Antiviral102725367
B6    I-Antiviral102725367
is    O
a    O
protein    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
SERPINB6    O
"    O
gene    O
.    O

Racivir    B-Antiviral102725367

Angustifodilactones    B-Antiviral102725367
are    O
natural    O
compounds    O
isolated    O
from    O
"    O
Kadsura    O
"    O
and    O
showing    O
some    O
activity    O
against    O
HIV    O
in    O
the    O
cell    O
culture    O
.    O

hepatitis    O
C    O
genotype    O
I    O
virus    O
—    O
can    O
be    O
treated    O
with    O
a    O
60    O
-    O
80%    O
success    O
rate    O
with    O
the    O
current    O
standard    O
-    O
of    O
-    O
care    O
treatment    O
of    O
interferon-α    O
,    O
ribavirin    O
and    O
recently    O
approved    O
protease    O
inhibitors    O
such    O
as    O
Telaprevir    B-Antiviral102725367
(    O
Incivek    O
)    O
May    O
2011    O
,    O
Boceprevir    B-Antiviral102725367
(    O
Victrelis    O
)    O
May    O
2011    O
or    O
the    O
nucleotide    O
analog    O
polymerase    O
inhibitor    O
Sofosbuvir    B-Antiviral102725367
(    O
Sovaldi    O
)    O
December    O
2013    O
.    O

Interferon    O
-    O
containing    O
regimens    O
may    O
also    O
include    O
protease    B-Antiviral102725367
inhibitors    I-Antiviral102725367
such    O
as    O
boceprevir    B-Antiviral102725367
and    O
telaprevir    B-Antiviral102725367
.    O

2,3-Bis(acetylmercaptomethyl)quinoxaline    B-Antiviral102725367
,    O
an    O
antiviral    O
agent    O

:    O
J05AX10    O
Maribavir    B-Antiviral102725367

Portmanteau    B-Antiviral102725367
inhibitor    I-Antiviral102725367
,    O
in    O
pharmaceuticals    O
,    O
a    O
drug    O
which    O
molecularly    O
combines    O
the    O
active    O
portions    O
of    O
two    O
inhibitor    O
-    O
class    O
drugs    O

moroxydine    B-Antiviral102725367
(    O
INN    O
)    O

Direct    B-Antiviral102725367
factor    I-Antiviral102725367
Xa    I-Antiviral102725367
inhibitors    I-Antiviral102725367
(    O
'    O
'    O
'    O
xabans    O
)    O
are    O
a    O
class    O
of    O
anticoagulant    O
drugs    O
which    O
act    O
directly    O
upon    O
Factor    O
X    O
in    O
the    O
coagulation    O
cascade    O
,    O
without    O
using    O
antithrombin    O
as    O
a    O
mediator    O
.    O

COX    O
inhibitors    O
(    O
namely    O
aspirin    O
)    O
,    O
warfarin    O
,    O
direct    B-Antiviral102725367
Xa    I-Antiviral102725367
inhibitor    I-Antiviral102725367
,    O
direct    O
thrombin    O
inhibitors    O
,    O
heparin    O
,    O
low    O
-    O
molecular    O
weight    O
heparins    O
,    O
antibodies    O
(    O
e.g.    O
,    O
abciximab    O
)    O
,    O
and    O
a    O
few    O
others    O
are    O
used    O
for    O
anticoagulation    O
therapy    O
.    O

It    O
is    O
being    O
investigated    O
as    O
an    O
HIV    O
entry    B-Antiviral102725367
inhibitor    I-Antiviral102725367
with    O
the    O
ability    O
to    O
block    O
both    O
CCR5-    O
and    O
CXCR4-tropic    O
viruses    O
,    O
and    O
is    O
undergoing    O
a    O
Phase    O
II    O
clinical    O
trial    O
with    O
an    O
estimated    O
study    O
completion    O
date    O
in    O
December    O
2010    O
.    O

Fostemsavir    B-Antiviral102725367
(    O
BMS-663068    B-Antiviral102725367
)    O
is    O
an    O
experimental    O
HIV    O
entry    B-Antiviral102725367
inhibitor    I-Antiviral102725367
and    O
a    O
prodrug    O
of    O
temsavir    O
(    O
BMS-626529    O
)    O
.    O

Entry    B-Antiviral102725367
inhibitor    I-Antiviral102725367

entry    B-Antiviral102725367
inhibitors    I-Antiviral102725367

Fusion    B-Antiviral102725367
inhibitor    I-Antiviral102725367

:    O
L03AB09    O
Interferon    B-Antiviral102725367
alfacon-1    I-Antiviral102725367

Potato    B-Antiviral102725367
carboxypeptidase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
,    O
a    O
natural    O
peptide    O
usable    O
for    O
thrombolytic    O
and    O
cancer    O
therapy    O

Alovudine    B-Antiviral102725367
was    O
an    O
antiviral    O
agent    O
being    O
developed    O
by    O
Medivir    O
,    O
which    O
was    O
discontinued    O
after    O
a    O
Phase    O
II    O
trial    O
in    O
2005    O
due    O
to    O
toxicity    O
.    O

Latest    O
evidence    O
suggests    O
that    O
Pegylated    B-Antiviral102725367
interferon    I-Antiviral102725367
alpha    I-Antiviral102725367
is    O
effective    O
in    O
reducing    O
the    O
viral    O
load    O
and    O
the    O
effect    O
of    O
the    O
disease    O
during    O
the    O
time    O
the    O
drug    O
is    O
given    O
,    O
but    O
the    O
benefit    O
generally    O
stops    O
if    O
the    O
drug    O
is    O
discontinued    O
.    O

NS5A    O
inhibitors    O
have    O
been    O
found    O
particularly    O
effective    O
in    O
the    O
treatment    O
of    O
HCV    O
where    O
they    O
have    O
been    O
used    O
in    O
combination    O
with    O
other    O
protease    O
inhibitors    O
such    O
as    O
NS5B    O
inhibitors    O
(    O
e.g.    O
sofosbuvir    B-Antiviral102725367
)    O
,    O
pegylated    B-Antiviral102725367
interferon    I-Antiviral102725367
(    O
e.g.    O
peginterferon    O
alfa-2a    O
)    O
,    O
and    O
ribonucleic    O
analogs    O
(    O
e.g.    O
ribavirin    O
)    O
.    O

Ciluprevir    B-Antiviral102725367
was    O
a    O
drug    O
used    O
experimentally    O
in    O
the    O
treatment    O
of    O
hepatitis    O
C.    O
It    O
is    O
manufactured    O
by    O
Boehringer    O
Ingelheim    O
and    O
developed    O
under    O
the    O
research    O
code    O
of    O
BILN    B-Antiviral102725367
2061    I-Antiviral102725367
.    O

Protein    B-Antiviral102725367
C    I-Antiviral102725367
inhibitor    I-Antiviral102725367
,    O
a    O
serine    O
protease    O
inhibitor    O

Tenofovir    B-Antiviral102725367
alafenamide    I-Antiviral102725367
—    O
a    O
nucleotide    O
reverse-transcriptase    B-Antiviral102725367
inhibitor    I-Antiviral102725367
that    O
uses    O
similar    O
phosphoramidate    O
prodrug    O
technology    O

Genvoya    B-Antiviral102725367
,    O
a    O
similar    O
drug    O
combination    O
but    O
with    O
tenofovir    O
"    O
alafenamide    O
"    O
instead    O
of    O
tenofovir    O
"    O
disoproxil    O
"    O

Fostemsavir    B-Antiviral102725367
(    O
BMS-663068    O
)    O
—    O
phase    O
III    O

Ulinastatin    B-Antiviral102725367
,    O
or    O
urinary    O
trypsin    O
inhibitor    O
(    O
UTI    O
)    O
is    O
a    O
glycoprotein    O
that    O
acts    O
as    O
a    O
trypsin    O
inhibitor    O
.    O

The    O
most    O
important    O
inhibitors    O
of    O
urokinase    O
are    O
the    O
serpins    O
plasminogen    O
activator    O
inhibitor-1    O
(    O
PAI-1    O
)    O
and    O
plasminogen    B-Antiviral102725367
activator    I-Antiviral102725367
inhibitor-2    I-Antiviral102725367
(    O
PAI-2    O
)    O
,    O
which    O
inhibit    O
the    O
protease    O
activity    O
irreversibly    O
.    O

Fibrinolysis    O
is    O
impaired    O
by    O
an    O
increase    O
in    O
plasminogen    O
activator    O
inhibitor-1    O
(    O
PAI-1    O
or    O
PAI    O
)    O
and    O
plasminogen    B-Antiviral102725367
activator    I-Antiviral102725367
inhibitor-2    I-Antiviral102725367
(    O
PAI-2    O
)    O
,    O
the    O
latter    O
synthesized    O
from    O
the    O
placenta    O
.    O

Rilpivirine    B-Antiviral102725367
(    O
TMC278    O
,    O
tradename    O
Edurant    O
)    O
,    O
an    O
NNRTI    O

Other    O
diarylpyrimidine    O
-    O
analogues    O
are    O
currently    O
being    O
used    O
as    O
anti    O
-    O
HIV    O
agents    O
,    O
notably    O
rilpivirine    B-Antiviral102725367
.    O

Foscarnet    B-Antiviral102725367
,    O
ganciclovir    O
,    O
tenofovir    O
,    O
adefovir    O
:    O
Risk    O
of    O
hematological    O
and    O
renal    O
side    O
effects    O
of    O
amphotericin    O
B    O
are    O
increased    O

In    O
terms    O
of    O
the    O
treatment    O
of    O
cytomegalovirus    O
retinitis    O
,    O
oral    O
valganciclovir    O
,    O
intravenous    O
ganciclovir    O
,    O
IV    O
foscarnet    B-Antiviral102725367
,    O
and    O
IV    O
cidofovir    O
are    O
all    O
efficient    O
in    O
the    O
treatment    O
of    O
this    O
condition    O
.    O

Also    O
intravitreal    O
injections    O
,    O
an    O
injection    O
of    O
medicine    O
into    O
the    O
vitreous    O
near    O
the    O
retina    O
,    O
of    O
foscarnet    B-Antiviral102725367
in    O
concomitance    O
with    O
oral    O
valganciclovir    O
can    O
be    O
used    O
for    O
treatment    O
as    O
well    O
.    O

The    O
first    O
is    O
Brincidofovir    B-Antiviral102725367
,    O
an    O
experimental    O
antiviral    O
drug    O
,    O
which    O
was    O
given    O
to    O
Duncan    O
,    O
Mukpo    O
,    O
and    O
Spencer    O
.    O

Brincidofovir    B-Antiviral102725367
,    O
another    O
antiviral    O
drug    O
,    O
has    O
been    O
granted    O
an    O
emergency    O
FDA    O
approval    O
as    O
an    O
investigational    O
new    O
drug    O
for    O
the    O
treatment    O
of    O
Ebola    O
after    O
it    O
was    O
found    O
to    O
be    O
effective    O
against    O
Ebola    O
virus    O
in    O
"    O
in    O
vitro    O
"    O
tests    O
.    O

hepatitis    O
C    O
genotype    O
I    O
virus    O
—    O
can    O
be    O
treated    O
with    O
a    O
60    O
-    O
80%    O
success    O
rate    O
with    O
the    O
current    O
standard    O
-    O
of    O
-    O
care    O
treatment    O
of    O
interferon-α    O
,    O
ribavirin    O
and    O
recently    O
approved    O
protease    O
inhibitors    O
such    O
as    O
Telaprevir    B-Antiviral102725367
(    O
Incivek    O
)    O
May    O
2011    O
,    O
Boceprevir    B-Antiviral102725367
(    O
Victrelis    O
)    O
May    O
2011    O
or    O
the    O
nucleotide    O
analog    O
polymerase    O
inhibitor    O
Sofosbuvir    B-Antiviral102725367
(    O
Sovaldi    O
)    O
December    O
2013    O
.    O

Interferon    O
-    O
containing    O
regimens    O
may    O
also    O
include    O
protease    B-Antiviral102725367
inhibitors    I-Antiviral102725367
such    O
as    O
boceprevir    B-Antiviral102725367
and    O
telaprevir    B-Antiviral102725367
.    O

3-Hydroxytetrahydrofuran    O
is    O
an    O
intermediate    O
to    O
the    O
AIDS    O
drugs    O
amprenavir    B-Antiviral102725367
and    O
fosamprenavir    O
.    O

Many    O
of    O
these    O
uses    O
have    O
been    O
exemplified    O
in    O
the    O
syntheses    O
of    O
various    O
pharmaceuticals    O
including    O
the    O
β-blocker    O
(    O
"    O
S")-propranolol    O
,    O
the    O
HIV    O
protease    O
inhibitor    O
Amprenavir    B-Antiviral102725367
(    O
Vertex    O
478    O
)    O
,    O
and    O
construction    O
of    O
the    O
carbohydrate    O
subunit    O
of    O
the    O
anthracycline    O
class    O
of    O
antibiotics    O
,    O
L    O
-    O
Acosamine    O
.    O

Examples    O
include    O
racecadotril    O
,    O
ubenimex    B-Antiviral102725367
(    O
bestatin    O
)    O
,    O
RB-101    O
,    O
and    O
D    O
-    O
phenylalanine    O
,    O
as    O
well    O
as    O
the    O
endogenous    O
opioid    O
peptides    O
opiorphin    O
and    O
spinorphin    O
.    O

The    O
advantages    O
of    O
genetic    O
adjuvants    O
are    O
their    O
low    O
cost    O
and    O
simple    O
administration    O
,    O
as    O
well    O
as    O
avoidance    O
of    O
unstable    O
recombinant    O
cytokines    O
and    O
potentially    O
toxic    O
,    O
“    O
conventional    O
”    O
adjuvants    O
(    O
such    O
as    O
alum    O
,    O
calcium    O
phosphate    O
,    O
monophosphoryl    O
lipid    O
A    O
,    O
cholera    O
toxin    O
,    O
cationic    O
and    O
mannan    O
-    O
coated    O
liposomes    O
,    O
QS21    O
,    O
carboxymethyl    O
cellulose    O
and    O
ubenimix    B-Antiviral102725367
)    O
.    O

Afovirsen    B-Antiviral102725367
is    O
an    O
oligonucleotide    O
capable    O
of    O
antisense    O
interactions    O
with    O
mRNA    O
of    O
human    O
papillomavirus    O
.    O

The    O
maturation    B-Antiviral102725367
inhibitors    I-Antiviral102725367
are    O
a    O
class    O
of    O
antiviral    O
drugs    O
for    O
the    O
treatment    O
of    O
infection    O
with    O
HIV    O
.    O

Denavir    B-Antiviral102725367

Purine    O
analogues    O
of    O
guanine    O
:    O
Aciclovir    O
,    O
Famciclovir    O
,    O
Ganciclovir    O
,    O
Penciclovir    B-Antiviral102725367
,    O
Valaciclovir    O
,    O
Valganciclovir    O

Angustific    B-Antiviral102725367
acid    I-Antiviral102725367

Integrase    B-Antiviral102725367
inhibitor    I-Antiviral102725367

Integrase    B-Antiviral102725367
inhibitors    I-Antiviral102725367
(    O
INIs    B-Antiviral102725367
)    O
are    O
a    O
class    O
of    O
antiretroviral    B-Antiviral102725367
drug    I-Antiviral102725367
designed    O
to    O
block    O
the    O
action    O
of    O
integrase    O
,    O
a    O
viral    O
enzyme    O
that    O
inserts    O
the    O
viral    O
genome    O
into    O
the    O
DNA    O
of    O
the    O
host    O
cell    O
.    O

The    O
class    O
of    O
integrase    O
inhibitors    O
called    O
integrase    B-Antiviral102725367
strand    I-Antiviral102725367
transfer    I-Antiviral102725367
inhibitors    I-Antiviral102725367
(    O
INSTIs    B-Antiviral102725367
)    O
are    O
in    O
established    O
use    O
.    O

Other    O
classes    O
,    O
such    O
as    O
integrase    B-Antiviral102725367
binding    I-Antiviral102725367
inhibitors    I-Antiviral102725367
(    O
INBIs    B-Antiviral102725367
)    O
,    O
are    O
still    O
experimental    O
.    O

Alpha    B-Antiviral102725367
2-antiplasmin    I-Antiviral102725367
(    O
or    O
α2-antiplasmin    B-Antiviral102725367
or    O
plasmin    B-Antiviral102725367
inhibitor    I-Antiviral102725367
)    O
is    O
a    O
serine    O
protease    O
inhibitor    O
(    O
serpin    O
)    O
responsible    O
for    O
inactivating    O
plasmin    O
.    O

This    O
protein    O
is    O
encoded    O
by    O
the    O
SERPINF2    B-Antiviral102725367
gene    O
.    O

Neutrophil    O
elastase    O
has    O
been    O
shown    O
to    O
interact    O
with    O
Alpha    B-Antiviral102725367
2-antiplasmin    I-Antiviral102725367
,    O
which    O
belongs    O
to    O
the    O
Serpin    O
family    O
of    O
proteins    O
.    O

Mbeki    O
's    O
ban    O
of    O
antiretroviral    B-Antiviral102725367
drugs    I-Antiviral102725367
in    O
public    O
hospitals    O
is    O
estimated    O
to    O
be    O
responsible    O
for    O
the    O
premature    O
deaths    O
of    O
between    O
330,000    O
and    O
365,000    O
people    O
.    O

CMMB    O
promotes    O
male    O
involvement    O
in    O
antenatal    O
clinics    O
and    O
responsibility    O
for    O
the    O
health    O
of    O
the    O
family    O
under    O
the    O
"    O
Men    O
Taking    O
Action    O
"    O
(    O
MTA™    O
)    O
model    O
,    O
including    O
PMTCT    O
,    O
HCT    O
services    O
,    O
and    O
antiretroviral    B-Antiviral102725367
(    O
ARV    O
)    O
treatment    O
at    O
31    O
participating    O
Church    O
Health    O
Institutions    O
.    O

Aciclovir    O
trials    O
show    O
that    O
this    O
agent    O
has    O
no    O
role    O
in    O
preventing    O
HIV    O
transmission    O
,    O
but    O
it    O
can    O
help    O
slow    O
HIV    O
disease    O
progression    O
in    O
people    O
not    O
taking    O
anti-retroviral    B-Antiviral102725367
therapy    I-Antiviral102725367
(ART)    I-Antiviral102725367
.    O

Viral    O
load    O
monitoring    O
for    O
HIV    O
is    O
the    O
regular    O
measurement    O
of    O
the    O
viral    O
load    O
of    O
individual    O
HIV    O
-    O
positive    O
people    O
as    O
part    O
of    O
their    O
personal    O
plan    O
for    O
treatment    B-Antiviral102725367
of    I-Antiviral102725367
HIV/AIDS    I-Antiviral102725367
.    O

Viral    O
load    O
monitoring    O
is    O
used    O
by    O
HIV    O
-    O
positive    O
people    O
to    O
develop    O
a    O
plan    O
for    O
their    O
personal    O
treatment    B-Antiviral102725367
of    I-Antiviral102725367
HIV/AIDS    I-Antiviral102725367
.    O

Highly    B-Antiviral102725367
active    I-Antiviral102725367
antiretroviral    I-Antiviral102725367
therapy    I-Antiviral102725367
(    O
HAART    O
)    O
is    O
the    O
current    O
recommended    O
treatment    O
for    O
HIV    O
.    O

Anti-retroviral    B-Antiviral102725367
therapy    I-Antiviral102725367
,    O
in    O
the    O
management    O
of    O
HIV    O
/    O
AIDS    O

The    O
increase    O
in    O
number    O
of    O
HIV    O
positive    O
Mozambicans    O
on    O
Antiretroviral    B-Antiviral102725367
treatment    I-Antiviral102725367
,    O
2003–14    O
.    O

According    O
to    O
the    O
report    O
named    O
"    O
Preventable    O
Fate    O
"    O
,    O
published    O
by    O
Doctors    O
without    O
Borders    O
,    O
25,000    O
Burmese    O
AIDS    O
patients    O
died    O
in    O
2007    O
,    O
deaths    O
that    O
could    O
largely    O
have    O
been    O
prevented    O
by    O
antiretroviral    B-Antiviral102725367
therapy    I-Antiviral102725367
drugs    O
and    O
proper    O
treatment    O
.    O

The    O
initiative    O
would    O
respond    O
to    O
a    O
shortage    O
of    O
antiretroviral    B-Antiviral102725367
drugs    I-Antiviral102725367
and    O
other    O
drugs    O
in    O
poorer    O
countries    O
,    O
where    O
the    O
vast    O
majority    O
of    O
AIDS    O
patients    O
receive    O
no    O
adequate    O
treatment    O
.    O

With    O
support    O
from    O
the    O
AIDS    O
Relief    O
program    O
and    O
in    O
collaboration    O
with    O
Catholic    O
Relief    O
Services    O
,    O
the    O
program    O
started    O
providing    O
antiretroviral    B-Antiviral102725367
medications    O
in    O
2004    O
and    O
so    O
far    O
close    O
to    O
2000    O
active    O
patients    O
are    O
benefiting    O
from    O
treatment    O
.    O

Antiretroviral    B-Antiviral102725367
drug    I-Antiviral102725367
and    O
treatment    O
of    O
opportunistic    O
infections    O

CFW    O
shops    O
do    O
not    O
distribute    O
antiretroviral    B-Antiviral102725367
drugs    O
.    O

Mitochondrial    O
toxicity    O
is    O
a    O
condition    O
in    O
which    O
the    O
mitochondria    O
of    O
a    O
body    O
's    O
cells    O
become    O
damaged    O
or    O
decline    O
significantly    O
in    O
number    O
;    O
it    O
occurs    O
as    O
a    O
side    O
effect    O
of    O
certain    O
antiretroviral    B-Antiviral102725367
drug    I-Antiviral102725367
used    O
to    O
treat    O
human    O
immunodeficiency    O
virus    O
,    O
or    O
HIV    O
.    O

However    O
,    O
on    O
24    O
November    O
2007    O
,    O
the    O
hospital    O
announced    O
that    O
this    O
ward    O
would    O
be    O
closed    O
because    O
beds    O
allocated    O
for    O
HIV    O
care    O
were    O
not    O
being    O
used    O
due    O
to    O
advances    O
in    O
HIV    O
treatment    O
(    O
namely    O
,    O
more    O
effective    O
anti-retroviral    B-Antiviral102725367
medications    O
)    O
,    O
resulting    O
in    O
fewer    O
patients    O
needing    O
to    O
be    O
admitted    O
for    O
HIV    O
/    O
AIDS    O
related    O
conditions    O
.    O

This    O
study    O
found    O
a    O
relationship    O
between    O
HIV    O
prevention    O
and    O
AIDS    B-Antiviral102725367
treatment    I-Antiviral102725367
.    O

A    O
study    O
by    O
the    O
South    O
African    O
National    O
Department    O
of    O
Health    O
and    O
the    O
Treasury    O
used    O
the    O
ASSA    O
model    O
to    O
project    O
a    O
positive    O
result    O
for    O
the    O
increased    O
implementation    O
of    O
antiretroviral    B-Antiviral102725367
drug    I-Antiviral102725367
(    O
ARV    O
)    O
in    O
the    O
country    O
,    O
although    O
their    O
cost    O
is    O
a    O
problem    O
.    O

The    O
organization    O
follows    O
a    O
community    O
-    O
based    O
medical    O
clinic    O
delivery    O
model    O
to    O
provide    O
primary    O
health    O
care    O
services    O
,    O
maternity    O
programs    O
,    O
HIV    O
/    O
AIDS    O
counseling    O
,    O
testing    O
and    O
ARV    B-Antiviral102725367
treatment    O
;    O
family    O
planning    O
,    O
and    O
immunizations    O
for    O
children    O
to    O
the    O
local    O
community    O
.    O

Michael    O
(    O
Mike    O
)    O
Simon    O
Youle    O
(    O
born    O
1960    O
)    O
is    O
a    O
British    O
doctor    O
and    O
clinical    O
researcher    O
specializing    O
in    O
HIV    B-Antiviral102725367
treatment    I-Antiviral102725367
.    O

Viral    O
load    O
monitoring    O
for    O
HIV    O
is    O
of    O
particular    O
interest    O
in    O
the    O
treatment    O
of    O
people    O
with    O
HIV    O
,    O
as    O
this    O
is    O
continually    O
discussed    O
in    O
the    O
context    O
of    O
management    B-Antiviral102725367
of    I-Antiviral102725367
HIV/AIDS    I-Antiviral102725367
.    O

Reverse-transcriptase    B-Antiviral102725367
inhibitors    I-Antiviral102725367
(    O
RTIs    B-Antiviral102725367
)    O
are    O
a    O
class    O
of    O
antiretroviral    B-Antiviral102725367
drug    I-Antiviral102725367
used    O
to    O
treat    O
HIV    O
infection    O
or    O
AIDS    O
,    O
and    O
in    O
some    O
cases    O
hepatitis    O
B.    O
RTIs    O
inhibit    O
activity    O
of    O
reverse    O
transcriptase    O
,    O
a    O
viral    O
DNA    O
polymerase    O
that    O
is    O
required    O
for    O
replication    O
of    O
HIV    O
and    O
other    O
retroviruses    O
.    O

It    O
is    O
used    O
in    O
combination    O
with    O
other    O
medications    O
as    O
part    O
of    O
highly    B-Antiviral102725367
active    I-Antiviral102725367
antiretroviral    I-Antiviral102725367
therapy    I-Antiviral102725367
(    O
HAART    O
)    O
.    O

Stavudine    O
(    O
d4    O
T    O
)    O
,    O
sold    O
under    O
the    O
brand    O
name    O
Zerit    O
among    O
others    O
,    O
is    O
an    O
antiretroviral    B-Antiviral102725367
medication    I-Antiviral102725367
used    O
to    O
prevent    O
and    O
treat    O
HIV    O
/    O
AIDS    O
.    O

Lamivudine    O
,    O
commonly    O
called    O
3TC    O
,    O
is    O
an    O
antiretroviral    B-Antiviral102725367
medication    I-Antiviral102725367
used    O
to    O
prevent    O
and    O
treat    O
HIV    O
/    O
AIDS    O
.    O

#    O
Autoimmune    O
disorders    O
have    O
been    O
reported    O
and    O
symptoms    O
can    O
occur    O
many    O
months    O
after    O
initiation    O
of    O
the    O
antiretroviral    B-Antiviral102725367
therapy    O
.    O

Similar    O
to    O
other    O
nucleoside    B-Antiviral102725367
reverse    I-Antiviral102725367
transcriptase    I-Antiviral102725367
inhibitor    I-Antiviral102725367
(    O
NRTIs    O
)    O
,    O
abacavir    O
is    O
used    O
together    O
with    O
other    O
HIV    B-Antiviral102725367
medications    I-Antiviral102725367
,    O
and    O
is    O
not    O
recommended    O
by    O
itself    O
.    O

In    O
January    O
2005    O
,    O
the    O
government    O
began    O
distributing    O
antiretroviral    B-Antiviral102725367
drugs    I-Antiviral102725367
,    O
hoping    O
to    O
reach    O
up    O
to    O
30,000    O
HIV    O
-    O
infected    O
adults    O
.    O

The    O
government    O
has    O
funded    O
an    O
antiretroviral    B-Antiviral102725367
drug    O
program    O
and    O
,    O
as    O
of    O
September    O
2006    O
,    O
more    O
than    O
80,000    O
HIV    O
/    O
AIDS    O
patients    O
had    O
received    O
such    O
drugs    O
.    O

Certain    O
antiretroviral    B-Antiviral102725367

Aml    O
Ameen    O
(    O
season    O
1    O
)    O
/    O
Toby    O
Onwumere    O
(    O
season    O
2    O
)    O
as    O
Capheus    O
"    O
Van    O
Damn    O
"    O
Onyango    O
,    O
a    O
matatu    O
driver    O
in    O
Nairobi    O
who    O
is    O
trying    O
to    O
earn    O
money    O
to    O
buy    O
HIV/AIDS    B-Antiviral102725367
medication    I-Antiviral102725367
for    O
his    O
mother    O
.    O

Cachexia    O
occurs    O
less    O
frequently    O
now    O
in    O
HIV    O
/    O
AIDS    O
than    O
in    O
the    O
past    O
due    O
to    O
the    O
advent    O
of    O
highly    B-Antiviral102725367
active    I-Antiviral102725367
antiretroviral    I-Antiviral102725367
therapy    I-Antiviral102725367
(    O
HAART    O
)    O
.    O

Efforts    O
to    O
reduce    O
drug    O
-    O
related    O
deaths    O
in    O
the    O
DTES    O
included    O
the    O
opening    O
of    O
a    O
needle    O
exchange    O
in    O
1989    O
,    O
the    O
opening    O
of    O
North    O
America    O
's    O
first    O
legal    O
safe    O
injection    O
site    O
in    O
2003    O
,    O
and    O
treatment    O
with    O
anti-retroviral    B-Antiviral102725367
drugs    I-Antiviral102725367
.    O

Duesberg    O
contends    O
that    O
HIV    O
is    O
a    O
harmless    O
passenger    O
virus    O
and    O
that    O
AIDS    O
is    O
caused    O
by    O
unrelated    O
factors    O
such    O
as    O
drug    O
abuse    O
,    O
antiretroviral    B-Antiviral102725367
medication    I-Antiviral102725367
,    O
chronic    O
malnutrition    O
,    O
poor    O
sanitation    O
,    O
and    O
hemophilia    O
.    O

Also    O
in    O
May    O
2004    O
,    O
CIDRZ    O
asked    O
RTI    O
whether    O
the    O
ZEPRS    O
software    O
could    O
be    O
adapted    O
to    O
help    O
in    O
managing    O
antiretroviral    B-Antiviral102725367
therapy    I-Antiviral102725367
(    O
ART    O
)    O
to    O
treat    O
patients    O
infected    O
with    O
the    O
Human    O
immunodeficiency    O
virus    O
(    O
HIV    O
)    O
.    O

Have    O
AIDS    O
(    O
unless    O
clinically    O
well    O
on    O
anti-retroviral    B-Antiviral102725367
therapy    I-Antiviral102725367
)    O

Hamied    O
is    O
best    O
known    O
outside    O
India    O
for    O
defying    O
large    O
Western    O
pharmaceutical    O
companies    O
in    O
order    O
to    O
provide    O
generic    O
AIDS    B-Antiviral102725367
drugs    I-Antiviral102725367
and    O
treatments    O
for    O
other    O
ailments    O
primarily    O
affecting    O
people    O
in    O
poor    O
countries    O
.    O

To    O
treat    O
his    O
infection    O
,    O
Morrison    O
said    O
he    O
took    O
antiretroviral    B-Antiviral102725367
medication    O
,    O
which    O
reduced    O
his    O
viral    O
load    O
to    O
almost    O
undetectable    O
levels    O
.    O

In    O
the    O
treatment    O
of    O
HIV    O
,    O
the    O
success    O
of    O
antiretroviral    B-Antiviral102725367
therapies    O
means    O
that    O
many    O
patients    O
will    O
experience    O
this    O
infection    O
as    O
a    O
chronic    O
disease    O
that    O
for    O
many    O
will    O
span    O
several    O
decades    O
of    O
their    O
life    O
.    O

Integrase    B-Antiviral102725367
inhibitors    I-Antiviral102725367
(    O
INIs    B-Antiviral102725367
)    O
are    O
a    O
class    O
of    O
antiretroviral    B-Antiviral102725367
drug    I-Antiviral102725367
designed    O
to    O
block    O
the    O
action    O
of    O
integrase    O
,    O
a    O
viral    O
enzyme    O
that    O
inserts    O
the    O
viral    O
genome    O
into    O
the    O
DNA    O
of    O
the    O
host    O
cell    O
.    O

Debates    O
on    O
the    O
ethics    O
of    O
provision    O
and    O
cost    O
of    O
anti-retroviral    B-Antiviral102725367
drugs    I-Antiviral102725367
,    O
particularly    O
in    O
poorer    O
countries    O
,    O
have    O
highlighted    O
inequalities    O
in    O
healthcare    O
and    O
stimulated    O
far    O
-    O
reaching    O
legislative    O
changes    O
.    O

iPrEx    O
(    O
from    O
,    O
"    O
pre    O
-    O
exposure    O
prophylaxis    O
initiative    O
"    O
)    O
was    O
a    O
phase    O
III    O
clinical    O
trial    O
to    O
determine    O
whether    O
the    O
antiretroviral    B-Antiviral102725367
medication    O
emtricitabine    O
/    O
tenofovir    O
(    O
as    O
tenofovir    O
disoproxil    O
fumarate    O
)    O
could    O
safely    O
and    O
effectively    O
prevent    O
HIV    O
acquisition    O
through    O
sex    O
in    O
men    O
who    O
have    O
sex    O
with    O
men    O
and    O
transgender    O
women    O
.    O

The    O
challenges    O
that    O
those    O
living    O
with    O
HIV    O
/    O
AIDS    O
face    O
can    O
be    O
the    O
result    O
of    O
the    O
viral    O
infection    O
itself    O
or    O
from    O
the    O
effects    O
of    O
anti    O
-    O
HIV    O
therapy    O
(    O
HAART    B-Antiviral102725367
)    O
.    O

Anti-retroviral    B-Antiviral102725367
treatments    I-Antiviral102725367
became    O
available    O
in    O
New    O
Zealand    O
in    O
about    O
1997    O
.    O

Upon    O
his    O
return    O
to    O
New    O
York    O
after    O
performing    O
research    O
in    O
South    O
Africa    O
in    O
the    O
late    O
1990s    O
,    O
Berkman    O
became    O
one    O
of    O
the    O
founders    O
of    O
Health    O
GAP    O
,    O
an    O
organization    O
dedicated    O
to    O
expanding    O
affordable    O
access    O
to    O
AIDS    O
medications    O
such    O
as    O
antiretroviral    B-Antiviral102725367
drugs    I-Antiviral102725367
in    O
the    O
poorest    O
parts    O
of    O
the    O
world    O
.    O

The    O
clinic    O
distributes    O
ARVs    B-Antiviral102725367
once    O
a    O
week    O
.    O

In    O
2013    O
,    O
following    O
a    O
clinical    O
trial    O
,    O
scientists    O
proposed    O
that    O
bone    O
marrow    O
transplantation    O
could    O
be    O
used    O
to    O
treat    O
HIV    O
in    O
conjunction    O
with    O
antiretroviral    B-Antiviral102725367
drugs    O
;    O
however    O
,    O
it    O
was    O
later    O
found    O
that    O
HIV    O
remained    O
in    O
the    O
bodies    O
of    O
the    O
test    O
subjects    O
.    O

He    O
is    O
known    O
for    O
his    O
work    O
on    O
HAART    B-Antiviral102725367
(    O
Highly    O
Active    O
Antiretroviral    O
Therapy    O
)    O
,    O
the    O
discovery    O
of    O
triple    O
therapy    O
as    O
an    O
effective    O
treatment    O
for    O
HIV    O
in    O
the    O
late    O
1990s    O
,    O
and    O
the    O
creation    O
of    O
the    O
“    O
Treatment    O
as    O
Prevention    O
”    O
Strategy    O
in    O
the    O
mid-2000s    O
.    O

After    O
he    O
was    O
appointed    O
the    O
Director    O
of    O
the    O
AIDS    O
Research    O
Program    O
and    O
the    O
Immunodeficiency    O
Clinic    O
at    O
St.    O
Paul    O
’s    O
Hospital    O
;    O
Montaner    O
focused    O
his    O
research    O
on    O
antiretroviral    B-Antiviral102725367
therapy    O
and    O
HIV    O
treatment    O
regimes    O
.    O

This    O
discovery    O
was    O
adopted    O
as    O
part    O
of    O
the    O
antiretroviral    O
treatment    O
guidelines    O
by    O
the    O
IAS    O
and    O
is    O
the    O
basis    O
of    O
the    O
modern    O
-    O
day    O
HAART    B-Antiviral102725367
treatment    O
regimen    O
.    O

Thereafter    O
,    O
antiretroviral    B-Antiviral102725367
treatment    I-Antiviral102725367
was    O
administered    O
and    O
easily    O
accessible    O
,    O
changing    O
the    O
patterns    O
of    O
HIV    O
/    O
AIDS    O
and    O
extending    O
the    O
lifespan    O
of    O
many    O
South    O
Africans    O
who    O
would    O
have    O
otherwise    O
died    O
at    O
an    O
earlier    O
age    O
.    O

Stribild    O
gained    O
approval    O
by    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
on    O
August    O
27    O
,    O
2012    O
for    O
use    O
in    O
adult    O
patients    O
starting    O
antiretroviral    B-Antiviral102725367
treatment    I-Antiviral102725367
for    O
the    O
first    O
time    O
as    O
part    O
of    O
the    O
fixed    O
dose    O
combination    O
.    O

Antiretrovirals    B-Antiviral102725367

Other    O
available    O
services    O
are    O
Comprehensive    O
Emergency    O
Maternal    O
and    O
Obstetrics    O
and    O
Neonatal    O
Care    O
(    O
CEmONC    O
)    O
,    O
Anti-retroviral    B-Antiviral102725367
therapy    I-Antiviral102725367
(    O
ART    O
)    O
,    O
and    O
an    O
Integrated    O
Counselling    O
Testing    O
Centre    O
(    O
ICTC    O
)    O
.    O

In    O
people    O
with    O
AIDS    O
,    O
a    O
large    O
number    O
of    O
opportunistic    O
organisms    O
has    O
been    O
known    O
to    O
cause    O
"    O
AIDS    O
cholangiopathy    O
"    O
,    O
but    O
the    O
risk    O
has    O
rapidly    O
diminished    O
since    O
the    O
introduction    O
of    O
effective    B-Antiviral102725367
AIDS    I-Antiviral102725367
treatment    I-Antiviral102725367
.    O

3    O
March    O
–    O
American    O
scientists    O
report    O
that    O
they    O
have    O
cured    O
HIV    O
in    O
an    O
infant    O
by    O
giving    O
the    O
child    O
a    O
course    O
of    O
antiretroviral    B-Antiviral102725367
drugs    O
very    O
early    O
in    O
its    O
life    O
.    O

Bone    O
marrow    O
transplants    O
are    O
found    O
to    O
remove    O
all    O
traces    O
of    O
HIV    O
from    O
two    O
test    O
patients    O
,    O
in    O
conjunction    O
with    O
antiretroviral    B-Antiviral102725367
treatments    O
.    O

At    O
the    O
hospital    O
,    O
he    O
is    O
tended    O
to    O
by    O
Dr.    O
Eve    O
Saks    O
(    O
Jennifer    O
Garner    O
)    O
,    O
who    O
tells    O
him    O
that    O
they    O
are    O
testing    O
a    O
drug    O
called    O
zidovudine    O
(    O
AZT    O
)    O
,    O
an    O
antiretroviral    B-Antiviral102725367
drug    I-Antiviral102725367
which    O
is    O
thought    O
to    O
prolong    O
the    O
life    O
of    O
AIDS    O
patients    O
—    O
and    O
is    O
the    O
only    O
drug    O
approved    O
by    O
the    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
for    O
testing    O
on    O
humans    O
.    O

Lipoatrophy    O
occurs    O
in    O
HIV    O
-    O
associated    O
lipodystrophy    O
,    O
one    O
cause    O
of    O
which    O
is    O
an    O
adverse    O
drug    O
reaction    O
that    O
is    O
associated    O
with    O
some    O
antiretroviral    B-Antiviral102725367
drug    I-Antiviral102725367
.    O

BAY    B-Antiviral102725367
57-1293    I-Antiviral102725367
,    O
AIC316    O
or    O
pritelivir    O

Serpin    B-Antiviral102725367
B4    I-Antiviral102725367
is    O
a    O
protein    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
SERPINB4    O
"    O
gene    O
.    O

Methisazone    B-Antiviral102725367
(    O
USAN    O
)    O
or    O
metisazone    B-Antiviral102725367
(    O
INN    O
)    O
is    O
an    O
antiviral    O
drug    O
that    O
works    O
by    O
inhibiting    O
mRNA    O
and    O
protein    O
synthesis    O
,    O
especially    O
in    O
pox    O
viruses    O
.    O

CYP3A4    O
inhibitors    O
,    O
which    O
increase    O
the    O
amount    O
of    O
felodipine    O
available    O
per    O
dose    O
,    O
include    O
cimetidine    O
,    O
erythromycin    O
,    O
itraconazole    O
,    O
ketoconazole    O
,    O
HIV    B-Antiviral102725367
protease    I-Antiviral102725367
inhibitors    I-Antiviral102725367
,    O
and    O
grapefruit    O
juice    O
.    O

Lasinavir    O
(    O
INN    O
,    O
previously    O
known    O
as    O
BMS-234475    O
and    O
CGP-61755    O
)    O
is    O
an    O
experimental    O
peptidomimetic    O
protease    B-Antiviral102725367
inhibitor    I-Antiviral102725367
researched    O
by    O
Novartis    O
and    O
Bristol    O
-    O
Myers    O
Squibb    O
as    O
a    O
treatment    O
for    O
HIV    O
infection    O
.    O

In    O
the    O
1990s    O
,    O
they    O
were    O
defined    O
as    O
a    O
serine    O
proteases    O
due    O
to    O
high    O
sequence    O
homology    O
with    O
alkaline    O
protease    O
,    O
and    O
their    O
inhibition    O
by    O
serine    B-Antiviral102725367
protease    I-Antiviral102725367
inhibitors    I-Antiviral102725367
(    O
Wang    O
et    O
al    O
.    O
,    O
1995    O
;    O
Taha    O
et    O
al    O
.    O
,    O
1998    O
and    O
Bressollier    O
et    O
a1    O
.    O
,    O
1999    O
)    O
.    O

Meristem    O
Therapeutics    O
–    O
Lipase    O
,    O
lactoferrin    O
,    O
plasma    O
proteins    O
,    O
collagen    O
,    O
antibodies    O
(    O
IgA    O
,    O
IgM    O
)    O
,    O
allergens    O
and    O
protease    B-Antiviral102725367
inhibitors    I-Antiviral102725367
in    O
tobacco    O
.    O
Liquidated    O
in    O
2008    O
.    O

Simeprevir    O
is    O
a    O
HCV    B-Antiviral102725367
protease    I-Antiviral102725367
inhibitor    I-Antiviral102725367
.    O

Simeprevir    O
is    O
a    O
hepatitis    O
C    O
virus    O
protease    B-Antiviral102725367
inhibitor    I-Antiviral102725367
.    O

It    O
's    O
also    O
contraindicated    O
if    O
patient    O
is    O
taking    O
Macrolide    O
antibiotics    O
(    O
eg    O
,    O
erythromycin    O
)    O
,    O
certain    O
HIV    O
protease    B-Antiviral102725367
inhibitors    I-Antiviral102725367
(    O
eg    O
,    O
ritonavir    O
,    O
nelfinavir    O
,    O
indinavir    O
)    O
,    O
certain    O
azole    O
antifungals    O
(    O
eg    O
,    O
ketoconazole    O
,    O
itraconazole    O
,    O
voriconazole    O
)    O
delavirdine    O
,    O
efavirenz    B-Antiviral102725367
or    O
a    O
5-HT1    O
agonist    O
(    O
eg    O
,    O
sumatriptan    O
)    O
.    O

protease    B-Antiviral102725367
inhibitor    I-Antiviral102725367
(    O
PIs    O
)    O

Examples    O
of    O
drugs    O
that    O
are    O
transition    O
state    O
analog    O
inhibitors    O
include    O
flu    O
medications    O
such    O
as    O
the    O
neuraminidase    B-Antiviral102725367
inhibitor    I-Antiviral102725367
oseltamivir    O
and    O
the    O
HIV    B-Antiviral102725367
protease    I-Antiviral102725367
inhibitor    I-Antiviral102725367
saquinavir    O
in    O
the    O
treatment    O
of    O
AIDS    O
.    O

Protease    B-Antiviral102725367
inhibitors    I-Antiviral102725367

Using    O
combinations    O
of    O
NRTIs    O
was    O
in    O
practice    O
prior    O
to    O
the    O
second    O
FDA    O
approval    O
and    O
the    O
triple    O
drug    O
combinations    O
with    O
dual    O
NRTIs    O
and    O
a    O
protease    B-Antiviral102725367
inhibitor    I-Antiviral102725367
(    O
PI    O
)    O
were    O
not    O
far    O
off    O
by    O
this    O
time    O
.    O

HIV    O
strains    O
that    O
are    O
resistant    O
to    O
protease    B-Antiviral102725367
inhibitors    I-Antiviral102725367
are    O
not    O
likely    O
to    O
be    O
resistant    O
to    O
abacavir    O
.    O

Protease    B-Antiviral102725367
inhibitors    I-Antiviral102725367
such    O
as    O
tipranavir    O
or    O
ritonovir    O
may    O
decrease    O
the    O
serum    O
concentration    O
of    O
abacavir    O
through    O
induction    O
of    O
glucuronidation    O
.    O

Interferon    O
-    O
containing    O
regimens    O
may    O
also    O
include    O
protease    B-Antiviral102725367
inhibitors    I-Antiviral102725367
such    O
as    O
boceprevir    B-Antiviral102725367
and    O
telaprevir    B-Antiviral102725367
.    O

Darunavir    B-Antiviral102725367
(    O
TMC114    O
,    O
tradename    O
Prezista    O
)    O
,    O
a    O
protease    B-Antiviral102725367
inhibitor    I-Antiviral102725367

He    O
helped    O
facilitate    O
the    O
production    O
of    O
protease    B-Antiviral102725367
inhibitor    I-Antiviral102725367
,    O
which    O
revolutionized    O
AIDS    O
care    O
in    O
the    O
1990s    O
.    O

He    O
worked    O
with    O
the    O
Food    O
and    O
Drug    O
Administration    O
's    O
Anti    O
-    O
Viral    O
Advisory    O
Committee    O
to    O
hasten    O
the    O
approval    O
time    O
for    O
new    O
HIV    O
medications    O
,    O
including    O
the    O
new    O
drug    O
class    O
of    O
protease    B-Antiviral102725367
inhibitor    I-Antiviral102725367
.    O

Nonstructural    O
protein    O
5A    O
(    O
NS5A    O
)    O
inhibitors    O
belong    O
to    O
a    O
class    O
of    O
antiviral    O
drugs    O
called    O
protease    B-Antiviral102725367
inhibitors    I-Antiviral102725367
.    O

The    O
drug    O
sofosbuvir    B-Antiviral102725367
had    O
been    O
part    O
of    O
the    O
2011    O
acquisition    O
of    O
Pharmasset    O
.    O

PRA    O
were    O
instrumental    O
in    O
supporting    O
Gilead    O
Sciences    O
,    O
Inc.    O
with    O
an    O
FDA    O
Breakthrough    O
Therapy    O
designation    O
for    O
Sovaldi    B-Antiviral102725367
(    O
Sofosbuvir    O
)    O
,    O
which    O
was    O
approved    O
by    O
the    O
FDA    O
in    O
December    O
2013    O
.    O

hepatitis    O
C    O
genotype    O
I    O
virus    O
—    O
can    O
be    O
treated    O
with    O
a    O
60    O
-    O
80%    O
success    O
rate    O
with    O
the    O
current    O
standard    O
-    O
of    O
-    O
care    O
treatment    O
of    O
interferon-α    O
,    O
ribavirin    O
and    O
recently    O
approved    O
protease    O
inhibitors    O
such    O
as    O
Telaprevir    B-Antiviral102725367
(    O
Incivek    O
)    O
May    O
2011    O
,    O
Boceprevir    B-Antiviral102725367
(    O
Victrelis    O
)    O
May    O
2011    O
or    O
the    O
nucleotide    O
analog    O
polymerase    O
inhibitor    O
Sofosbuvir    B-Antiviral102725367
(    O
Sovaldi    O
)    O
December    O
2013    O
.    O

Merck    O
deceptively    O
obtained    O
the    O
formula    O
to    O
Sovaldi    B-Antiviral102725367
over    O
a    O
conference    O
call    O
with    O
Pharmasset    O
.    O

Hetero    O
also    O
produces    O
affordable    O
hepatitis    O
C    O
antivirals    O
such    O
as    O
Sofovir    O
(    O
sofosbuvir    B-Antiviral102725367
)    O
and    O
Ledifos    O
(    O
a    O
fixed    O
-    O
dose    O
combination    O
of    O
sofosbuvir    B-Antiviral102725367
and    O
ledipasvir    O
)    O
.    O

NS5A    O
inhibitors    O
have    O
been    O
found    O
particularly    O
effective    O
in    O
the    O
treatment    O
of    O
HCV    O
where    O
they    O
have    O
been    O
used    O
in    O
combination    O
with    O
other    O
protease    O
inhibitors    O
such    O
as    O
NS5B    O
inhibitors    O
(    O
e.g.    O
sofosbuvir    B-Antiviral102725367
)    O
,    O
pegylated    B-Antiviral102725367
interferon    I-Antiviral102725367
(    O
e.g.    O
peginterferon    O
alfa-2a    O
)    O
,    O
and    O
ribonucleic    O
analogs    O
(    O
e.g.    O
ribavirin    O
)    O
.    O

Interferon    B-Antiviral102725367
tau    I-Antiviral102725367
is    O
a    O
Type    O
I    O
interferon    O
made    O
up    O
of    O
a    O
single    O
chain    O
of    O
amino    O
-    O
acids    O
.    O

Tecovirimat    B-Antiviral102725367
(    O
ST-246    B-Antiviral102725367
)    O
is    O
an    O
antiviral    O
with    O
activity    O
against    O
orthopoxviruses    O
such    O
as    O
smallpox    O
and    O
is    O
currently    O
undergoing    O
clinical    O
trials    O
.    O

Hemispherx    O
has    O
conducted    O
research    O
on    O
a    O
by    B-Antiviral102725367
mouth    I-Antiviral102725367
versions    I-Antiviral102725367
of    O
rintatolimod    O
using    O
nucleic    O
acid    O
technology    O
related    O
to    O
rintatolimod    O
.    O

Aliskiren    O
is    O
a    O
renin    B-Antiviral102725367
inhibitor    I-Antiviral102725367
,    O
which    O
works    O
to    O
reduce    O
primary    O
hypertension    O
(    O
that    O
with    O
no    O
known    O
cause    O
)    O
by    O
binding    O
to    O
renin    O
and    O
preventing    O
it    O
from    O
initiating    O
the    O
renin    O
-    O
angiotensin    O
system    O
(    O
RAAS    O
)    O
pathway    O
to    O
increase    O
blood    O
pressure    O
.    O

Aliskiren    O
(    O
developed    O
by    O
Novartis    O
)    O
is    O
a    O
renin    B-Antiviral102725367
inhibitor    I-Antiviral102725367
which    O
has    O
been    O
approved    O
by    O
the    O
U.S.    O
FDA    O
for    O
the    O
treatment    O
of    O
hypertension    O
.    O

Aliskiren    O
(    O
trade    O
names    O
Tekturna    O
and    O
Rasilez    O
)    O
is    O
the    O
first    O
in    O
a    O
class    O
of    O
drugs    O
called    O
direct    O
renin    B-Antiviral102725367
inhibitors    I-Antiviral102725367
.    O

Methoxy    B-Antiviral102725367
arachidonyl    I-Antiviral102725367
fluorophosphonate    I-Antiviral102725367
,    O
commonly    O
referred    O
as    O
MAFP    B-Antiviral102725367
,    O
is    O
an    O
irreversible    O
active    O
site    O
-    O
directed    O
enzyme    O
inhibitor    O
that    O
inhibits    O
nearly    O
all    O
serine    O
hydrolases    O
and    O
serine    O
proteases    O
.    O

Tosyl    B-Antiviral102725367
phenylalanyl    I-Antiviral102725367
chloromethyl    I-Antiviral102725367
ketone    I-Antiviral102725367
(    O
TPCK    B-Antiviral102725367
)    O
is    O
a    O
protease    O
inhibitor    O
.    O

The    O
interaction    O
between    O
sofosbuvir    O
and    O
a    O
number    O
of    O
other    O
drugs    O
,    O
such    O
as    O
ciclosporin    O
,    O
darunavir    B-Antiviral102725367
/    O
ritonavir    O
,    O
efavirenz    B-Antiviral102725367
,    O
emtricitabine    O
,    O
methadone    O
,    O
raltegravir    B-Antiviral102725367
,    O
rilpivirine    B-Antiviral102725367
,    O
tacrolimus    O
,    O
or    O
tenofovir    O
disoproxil    O
,    O
were    O
evaluated    O
in    O
clinical    O
trials    O
and    O
no    O
dose    O
adjustment    O
is    O
needed    O
for    O
any    O
of    O
these    O
drugs    O
.    O

Darunavir    B-Antiviral102725367

Darunavir    B-Antiviral102725367
(    O
TMC114    O
,    O
tradename    O
Prezista    O
)    O
,    O
a    O
protease    B-Antiviral102725367
inhibitor    I-Antiviral102725367

Neokadsuranin    B-Antiviral102725367

Acemannan    B-Antiviral102725367
is    O
a    O
D    O
-    O
isomer    O
mucopolysaccharide    O
in    O
aloe    O
vera    O
leaves    O
.    O

Prinomastat    O
(    O
code    O
name    O
AG-3340    O
)    O
is    O
a    O
matrix    O
metalloproteinase    O
(    O
MMP    O
)    O
inhibitor    B-Antiviral102725367
with    O
specific    O
selectivity    O
for    O
MMPs    O
2    O
,    O
3    O
,    O
9    O
,    O
13    O
,    O
and    O
14    O
.    O

Examples    O
of    O
drugs    O
that    O
are    O
transition    O
state    O
analog    O
inhibitors    O
include    O
flu    O
medications    O
such    O
as    O
the    O
neuraminidase    B-Antiviral102725367
inhibitor    I-Antiviral102725367
oseltamivir    O
and    O
the    O
HIV    B-Antiviral102725367
protease    I-Antiviral102725367
inhibitor    I-Antiviral102725367
saquinavir    O
in    O
the    O
treatment    O
of    O
AIDS    O
.    O

Neuraminidase    B-Antiviral102725367
inhibitor    I-Antiviral102725367
inhibit    O
enzymatic    O
activity    O
of    O
the    O
enzyme    O
neuraminidase    O
(    O
sialidase    O
)    O
.    O

Neuraminidase    B-Antiviral102725367
inhibitors    I-Antiviral102725367

In    O
1992    O
,    O
Stevens    O
worked    O
with    O
researchers    O
at    O
Gilead    O
on    O
the    O
structural    O
studies    O
of    O
neuraminidase    B-Antiviral102725367
inhibitor    I-Antiviral102725367
that    O
eventually    O
became    O
Tamiflu    O
,    O
and    O
later    O
partnered    O
with    O
Roche    O
.    O

Tilorone    B-Antiviral102725367
(    O
trade    O
names    O
Amixin    B-Antiviral102725367
,    O
Lavomax    B-Antiviral102725367
and    O
others    O
)    O
is    O
the    O
first    O
recognized    O
synthetic    O
,    O
small    O
molecular    O
weight    O
compound    O
that    O
is    O
an    O
orally    O
active    O
interferon    O
inducer    O
.    O

E-64    B-Antiviral102725367
,    O
an    O
epoxide    O
which    O
can    O
irreversibly    O
inhibit    O
a    O
wide    O
range    O
of    O
cysteine    O
peptidases    O

Inosine    B-Antiviral102725367
pranobex    I-Antiviral102725367

Under    O
the    O
name    O
dimepranol    O
,    O
it    O
is    O
also    O
used    O
as    O
an    O
ingredient    O
in    O
some    O
pharmaceutical    O
formulations    O
such    O
as    O
dimepranol    O
acedoben    O
,    O
a    O
component    O
of    O
inosine    B-Antiviral102725367
pranobex    I-Antiviral102725367
.    O


